Ceftobripole: Experience in staphylococcal bacteremia

• Autores: Alex Soriano, Laura Morata
• Localización: Revista Española de Quimioterapia, ISSN-e 0214-3429, Vol. 32, Nº Extra 3 (September Suppl.3):1-36), 2019, págs. 24-28
• Idioma: inglés
• Enlaces
  • Texto completo (pdf)
• Resumen

  • Ceftobiprole is a new cephalosporin with an extended spectrum activity against the majority of microorganisms isolated in bacteremia including methicillin-susceptible (MSSA) and -resistant S. aureus (MRSA). This antibiotic has demonstrated a potent activity against MRSA in animal models of endocarditis in monotherapy but particularly in combination with daptomycin, suggesting that this combination could be a future option to improve the outcome of staphylococcal endovascular infections. In addition, the extended-spectrum ceftobiprole activity, including coagulase-negative staphylococci, Enterococcus faecalis, Enterobacteriaceae and Pseudomonas aeruginosa represents an advantage for use as empirical therapy in bacteremia potentially caused by a broad spectrum of microorganisms, such as in catheter-related bacteremia.